| abstract |
The invention relates to new substituted heteroaryls of formula 1 or of formula 1' wherein A is either N or CH, wherein R 2 is selected from the group consisting of -C 1-3 -alkyl, -C 1-3 -haloalkyl, F, Br, CI, wherein Y is selected from -O- or -CH 2 -, and wherein R 3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof, and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis. |